TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2860167
Drug: Daily antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antiseptic mouthwash with chlorhexidine‐gluconate
Study: 2860167
Drug: Daily antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antiseptic mouthwash with povidone‐iodine
Study: 2860167
Drug: Hygienic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygienic treatment alone
Study: 31179831
Drug: Levothyroxine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (20 μg bolus followed by 20 μg/h infusion)
Study: 21816692
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for diabetes
Study: 16458200
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (500 mg, twice daily; 2 weeks)
Study: 9213203
Drug: bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (10 mg q.d.)
Study: 9213203
Drug: lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (20 mg q.d.)
Study: 10779310
Drug: 0.05 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/m2 rIFN-gamma
Study: 3315914
Drug: oral ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ketanserin (20 mg X 7)
Study: 27132409
Drug: DermoXEN Vitexyl
Normalized name: Dermoneen
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DermoXEN Vitexyl vaginal gel
Study: 24604487
Drug: Shared care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared care model of follow-up visits in the first 12 months after treatment, including a survivorship care plan, GP management guidelines, register and recall systems, screening for distress and unmet needs, and patient information resources.
Study: 23690424
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus brivanib 800 mg orally daily
Study: 16630383
Drug: Twice-weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly iron supplementation (ferrous dextran, 60 mg elemental iron)
Study: 8911006
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms OprI vaccine
Study: 8911006
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms OprI vaccine
Study: 8911006
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms OprI vaccine
Study: 8911006
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms OprI vaccine
Study: 1729038
Drug: Continuous iv
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv infusion of furosemide (initial dose 0.1 mg/kg iv, infusion rate 0.1 mg/kg.hr, doubled every 2 hrs to max 0.4 mg/kg.hr)
Study: 1729038
Drug: Intermittent iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent iv infusion of furosemide (1 mg/kg iv every 4 hrs, increased by 0.25 mg/kg every 4 hrs to max 1.5 mg/kg)
Study: 6339571
Drug: Thymopoietin pentapeptide
Normalized name: pentapeptide-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopoietin pentapeptide (TP-5) 50 mg, thrice-weekly injections for 6 weeks
Study: 31607271
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (part of a randomized trial)
Study: 25160064
Drug: Weekly standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly standardized SMS
Study: 25160064
Drug: Weekly standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly standardized supervisory visits
Study: 18728038
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of low-dose aspirin (Control)
Study: 11087965
Drug: mCPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCPP (0.5 mg/kg body weight)
Study: 3282893
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg b.i.d. (increased to 10 mg b.i.d. if needed)
Study: 3282893
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg b.i.d. (increased to 25 mg b.i.d. if needed)
Study: 11341663
Drug: Coffee (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (280 ml)
Study: 29374995
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection (IO)
Study: 20665501
Drug: IA combination
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA combination (idarubicin and cytarabine)
Study: 17602073
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg infused over 10 minutes
Study: 17602073
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg infused over 30 minutes
Study: 17602073
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg infused at a standard rate of 0.5 mg/kg/min
Study: 16040284
Drug: Levofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (300 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Study: 16040284
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Study: 12556743
Drug: Catheter-directed thrombolytic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed thrombolytic therapy using urokinase
Study: 12556743
Drug: Catheter-directed thrombolytic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed thrombolytic therapy
Study: 12556743
Drug: Anticoagulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation with unfractionated or low molecular weight heparin followed by warfarin
Study: 7795270
Drug: TMQ at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMQ at 200 mg/m2 i.v. q 2 weeks
Study: 7795270
Drug: TMQ at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMQ at 12 mg/m2 i.v. daily x 5
Study: 7795270
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 15 mg/kg i.v. weekly
Study: 6971922
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement of 400 IU/day
Study: 29390477
Drug: Drotaverine hydrochloride
Normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine hydrochloride (DHC) 80‐mg tablet, 3 times daily for 4 weeks
Study: 29390477
Drug: Placebo 80‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 80‐mg tablet, 3 times daily for 4 weeks
Study: 22000773
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine (120 μg for the right coronary artery and 180 μg for the left coronary artery)
Study: 19685728
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) of Ashi-point, Jiaji (EX‐B 2), Zhigou (SJ 6) and Houxi (SI 3), once daily for 10 times
Study: 19685728
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (valaciclovir hydrochloride 300 mg/time, b.i.d. and vitamin B1 10 mg/time, t.i.d., for 10 days)
Study: 15640898
Drug: Solanum melongena
Normalized name: SOLANUM MELONGENA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanum melongena (SM) 450 mg twice daily
Study: 15640898
Drug: Placebo 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 450 mg twice daily
Study: 11584350
Drug: Telephone nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone nursing intervention weekly for 3 months
Study: 10099041
Drug: Tiagabine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (titrated from 8 to 24 mg/d)
Study: 8136389
Drug: Hypodense solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodense solution of mannitol (n = 23)
Study: 8136389
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of BaSO4 (n = 14)
Study: 2491962
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (hexamethylmelamine, 5‐fluorouracil, cisplatin, and prednimustine)
Study: 23451885
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) 120 mg twice daily
Study: 18854724
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER < or =225 mg/day
Study: 16614416
Drug: CAF in
Normalized name: Zincaf Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF in capsule form (4.45 mg/kg body weight)
Study: 16614416
Drug: RCOF (4.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCOF (4.45 mg/kg body weight caffeine)
Study: 31488494
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral azithromycin (20 mg/kg)
Study: 7688381
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (200 mg orally) 12 hours before surgical interruption
Study: 7688381
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (200 mg orally) 24 hours before surgical interruption
Study: 3091164
Drug: Captopril (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25‐50 mg twice a day)
Study: 3091164
Drug: Captopril (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12 weeks treatment)
Study: 24646101
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog injections plus daily topical testosterone gel
Study: 18636265
Drug: Single intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of 1.25 mg bevacizumab
Study: 18636265
Drug: Second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second injection of bevacizumab after a mean of 19+/‐8 weeks
Study: 18636265
Drug: Second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second injection of bevacizumab
Study: 17336650
Drug: Mild treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild treatment (mild ovarian stimulation with GnRH antagonist co-treatment and single embryo transfer)
Study: 17336650
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (stimulation with GnRH agonist long-protocol and transfer of two embryos)
Study: 17336650
Drug: Mild treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild treatment
Study: 12691137
Drug: Tyrosine-kinase inhibitor
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine-kinase inhibitor STI 571
Study: 29164312
Drug: Rotigotine in
Normalized name: Product containing rotigotine in transdermal dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine in combination with levodopa
Study: 20368905
Drug: Iloperidone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone (12 to 24 mg)
Study: 16633107
Drug: Octreotide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (300 microg twice per day) with diuretics (furosemide and spironolactone)
Study: 16633107
Drug: Octreotide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (300 microg twice per day) alone
Study: 16633107
Drug: Diuretics (furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (furosemide and spironolactone) alone
Study: 16633107
Drug: Diuretics (furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (furosemide and spironolactone) discontinued for 7 days
Study: 1405984
Drug: Sucralfate, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, given four times daily for 10 days as a swish and swallow
Study: 4078027
Drug: Intravenous indoprofen
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous indoprofen 200 mg
Study: 4078027
Drug: Intravenous indoprofen
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous indoprofen 400 mg
Study: 4078027
Drug: Intramuscular pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pentazocine 15 mg
Study: 4078027
Drug: Intramuscular pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pentazocine 30 mg
Study: 28358246
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blocker (ARB)
Study: 22951521
Drug: Non-dihydropyridine calcium
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-dihydropyridine calcium channel blocker (CCB)
Study: 18677237
Drug: Chronic protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic protection (1 week prophylactic use of the solution)
Study: 18677237
Drug: Unprotected (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprotected (no test solution used)
Study: 18677237
Drug: Immediate protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate protection (test solution instilled just before application of TST)
Study: 18677237
Drug: Relief (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relief (test solution instilled just after application of TST)
Study: 10390264
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime for 14 days (double dose on day 1)
Study: 10390264
Drug: Initial intravenous
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intravenous cefotaxime for 3 days followed by oral cefixime for 11 days
Study: 8814691
Drug: Oral pamidronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate, 300 mg/day (n = 65)
Study: 2004793
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (20 mg)
Study: 2004793
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 ml dextrose)
Study: 23422357
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake (high quintile >371 mg/day)
Study: 21703023
Drug: Clinician reminders
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician reminders to reconsider aspirin
Study: 21703023
Drug: Clinician and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician and patient messages to reconsider aspirin
Study: 19335932
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) plus Treatment as Usual (TAU)
Study: 15498043
Drug: Daily supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplement of vitamins (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Study: 11280825
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy (FLEC protocol), median of 3.5 cycles
Study: 11280825
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy (FLEC protocol)
Study: 8168798
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment in jail
Study: 2889457
Drug: CGP 361
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 361 A (10 mg)
Study: 25957748
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dronabinol (Marinol®)
Study: 25957748
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dronabinol (Marinol®)
Study: 22553980
Drug: Dronabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (10 mg and 20 mg)
Study: 21327759
Drug: Nicotine administration
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine administration in abstinent smokers
Study: 21327759
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration in abstinent smokers
Study: 21327759
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration in abstinent smokers
Study: 15176654
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg formulation 1
Study: 15176654
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg formulation 2
Study: 15176654
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg formulation 1 and 2
Study: 11205494
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for Helicobacter pylori infection and daily dietary supplementation with antioxidant micronutrients
Study: 8955577
Drug: Magic Lite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magic Lite (ML)
Study: 25336068
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga intervention (12-week, twice-weekly)
Study: 16542201
Drug: Tezosentan (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (2.5, 5.0, 12.5 and 25 mg h(‐1))
Study: 9489813
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment for RA
Study: 7836695
Drug: D-propoxyphene (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-propoxyphene (0.7 mg/kg body weight)
Study: 3402341
Drug: Routine weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine weekly catheter replacement
Study: 29659956
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice polyphenols (GJPs) 300 mg/d for 1 month
Study: 26053138
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of galactose/day followed by 500 mg for 2 weeks
Study: 23641006
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) ON
Study: 19051551
Drug: Oral B‐‐alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B‐‐alcohol free
Study: 19051551
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching agent (Vivastyle)
Study: 16815189
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine (65 mug kg(‐1) morphine sulphate, 3 mL via oral nebulizer)
Study: 16815189
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (physiological saline, 3 mL via oral nebulizer)
Study: 16815189
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine
Study: 15124547
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy in stage IIb and higher seminoma
Study: 10882586
Drug: Protease inhibitor-containing
Normalized name: Protease inhibitor-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-containing regimen
Study: 7565327
Drug: Symptomatic therapies,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapies, ampicillin, co‐trimoxazole
Study: 20492840
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg/d)
Study: 17012455
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate 20 mg, administered three times per day for 1 week, then 20 mg per day for the next 3 weeks
Study: 17012455
Drug: Monophasic combination
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic combination oral contraceptive (OC) containing 1 mg norethindrone and 35 mcg of ethinyl estradiol, administered three times per day for 1 week, then one tablet per day for the next 3 weeks
Study: 15040791
Drug: Patient information
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient information booklet about menorrhagia and treatment options, mailed before the first visit to the outpatient clinic.
Study: 10740328
Drug: Oral trimegestone
Normalized name: promegestone
DrugBank: Promegestone (DB13602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day)
Study: 1280464
Drug: Additional radiotherapy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional radiotherapy after chemotherapy
Study: 1280464
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment or additional chemotherapy
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol in normal renal function
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol in mild renal impairment
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol in moderate renal impairment